Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS)

被引：1
|
作者：
Stewart, David J.
Bosse, Dominick
Hilton, John Frederick
Goss, Glenwood D.
Fung-Kee-Fung, Michael
Jonker, Derek J.
机构：
[1] Ottawa Hosp, Ottawa, ON, Canada
[2] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[3] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[4] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.6556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6556
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Concordance index: Surrogacy of progression-free survival for overall survival
    Fan, Yiwei
    Yin, Guosheng
    CONTEMPORARY CLINICAL TRIALS, 2021, 104
  • [42] Evaluation of overall survival (OS), progression-free survival (PFS), or time to progression (TTP) in systematic review of randomized clinical trials (RCT) in patients with metastatic breast cancer (MBC)
    Mukonje, Terence
    Santana-Davila, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Takigawa, N.
    Tabata, M.
    Fujiwara, Y.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials
    Pasalic, Dario
    McGinnis, Gwendolyn J.
    Fuller, C. David
    Grossberg, Aaron J.
    Verma, Vivek
    Mainwaring, Walker
    Miller, Austin B.
    Lin, Timothy A.
    Jethanandani, Amit
    Espinoza, Andres F.
    Diefenhardt, Markus
    Das, Prajnan
    Subbiah, Vivek
    Subbiah, Ishwaria M.
    Jagsi, Reshma
    Garden, Adam S.
    Fokas, Emmanouil
    Roedel, Claus
    Thomas, Charles R., Jr.
    Minsky, Bruce D.
    Ludmir, Ethan B.
    EUROPEAN JOURNAL OF CANCER, 2020, 136 : 176 - 185
  • [45] APPROACHES USED TO MODEL THE RELATIONSHIP BETWEEN PROGRESSION-FREE SURVIVAL (PFS) / TIME-TO-PROGRESSION (TTP) AND OVERALL SURVIVAL (OS) WITHIN HEALTH ECONOMIC MODELS OF CANCER THERAPIES
    Rafia, R.
    Ward, S. E.
    VALUE IN HEALTH, 2014, 17 (07) : A557 - A557
  • [46] The prognostic effects of performance status (PS) and quality of life (QoL) scores on progression-free survival (PFS) and overall survival (OS) in advanced ovarian cancer.
    Carey, M. S.
    Bacon, M.
    Tu, D.
    Bezjak, A.
    Stuart, G. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 272S - 272S
  • [47] Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors
    Kanamori, Masayuki
    Kumabe, Toshihiro
    Sonoda, Yukihiko
    Nishino, Yoshikazu
    Watanabe, Mika
    Tominaga, Teiji
    JOURNAL OF NEURO-ONCOLOGY, 2009, 93 (02) : 219 - 228
  • [48] PROGRESSION-FREE SURVIVAL (PFS) IS CORRELATED WITH OVERALL SURVIVAL (OS) IN CLINICAL STUDIES OF TARGETED THERAPIES PLUS CHEMOTHERAPY IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC)
    Sidhu, Roger
    Rong, Alan
    Dahlberg, Steve
    ANNALS OF ONCOLOGY, 2011, 22 : v120 - v120
  • [49] Nomograms for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.
    Sjoquist, Katrin Marie
    Renfro, Lindsay A.
    Simes, John
    Tebbutt, Niall C.
    Clarke, Stephen John
    Meyers, Jeffrey P.
    Gonsalves, Wilson I.
    Adams, Richard
    Seymour, Matthew T.
    Saltz, Leonard
    Schmoll, Hans
    Sargent, Daniel J.
    De Gramont, Aimery
    Zalcberg, John Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [50] Does absolute gain in progression-free survival (PFS) half-life (t1/2) translate into absolute overall survival (OS) benefit?
    Bosse, Dominick
    Boucher, Julie
    Vickers, Michael M.
    Stewart, David J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345